Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers

References

• Eicher JD, Xue L, Ben-Shlomo Y, et al. (2016). Replication and hematological characterization of human platelet reactivity genetic associations in men from the Caerphilly Prospective Study (CaPS). J Thromb Thrombolysis 41:343–50
   PubMed Web of Science ®Google Scholar
• Faraday N, Yanek LR, Yang XP, et al. (2011). Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118:3367–75
   PubMed Web of Science ®Google Scholar
• Fisch AS, Yerges-Armstrong LM, Backman JD, et al. (2015). Genetic variation in the platelet endothelial aggregation receptor 1 gene results in endothelial dysfunction. PLoS One 10:e0138795
   PubMed Web of Science ®Google Scholar
• Guo X, Chen XP, Cheng ZN, et al. (2009). No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med 47:38–43
   PubMed Web of Science ®Google Scholar
• Haufroid V, Mourad M, Van Kerckhove V, et al. (2004). The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147–54
   PubMedGoogle Scholar
• Herrera-Galeano JE, Becker DM, Wilson AF, et al. (2008). A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol 28:1484–90
   PubMed Web of Science ®Google Scholar
• Johnson AD, Yanek LR, Chen MH, et al. (2010). Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42:608–13
   PubMed Web of Science ®Google Scholar
• Jones CI, Bray S, Garner SF, et al. (2009). A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 114:1405–16
   PubMed Web of Science ®Google Scholar
• Kauskot A, Di Michele M, Loyen S, et al. (2012). A novel mechanism of sustained platelet alphaIIbbeta3 activation via PEAR1. Blood 119:4056–65
   PubMed Web of Science ®Google Scholar
• Kauskot A, Vandenbriele C, Louwette S, et al. (2013). PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood 121:5208–17
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, Park JY. (2008). The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236–42
   PubMed Web of Science ®Google Scholar
• Kim Y, Suktitipat B, Yanek LR, et al. (2013). Targeted deep resequencing identifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS One 8:e64179
   PubMed Web of Science ®Google Scholar
• Lewis JP, Ryan K, O'connell JR, et al. (2013). Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 6:184–92
   PubMed Web of Science ®Google Scholar
• Li MP, Tang J, Wen ZP, et al. (2015). Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Blood Coagul Fibrinolysis 26:874–81
   PubMed Web of Science ®Google Scholar
• Li MP, Xiong Y, Xu A, et al. (2014). Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Int J Hematol 99:263–71
   PubMed Web of Science ®Google Scholar
• Nanda N, Phillips DR. (2006). Novel targets for antithrombotic drug discovery. Blood Cells Mol Dis 36:228–31
   PubMed Web of Science ®Google Scholar
• Olivi L, Vandenbriele C, Gu YM, et al. (2015). PEAR1 is not a human hypertension-susceptibility gene. Blood Press 24:61–4
   PubMed Web of Science ®Google Scholar
• Postula M, Kaplon-Cieslicka A, Rosiak M, et al. (2011). Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost 9:2291–301
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, et al. (2012). Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59:1928–37
   PubMed Web of Science ®Google Scholar
• Qayyum R, Becker LC, Becker DM, et al. (2015). Genome-wide association study of platelet aggregation in African Americans. BMC Genet 16:58
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG. (2015). Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition? Haematologica 100:1103–5
   PubMed Web of Science ®Google Scholar
• Sokol J, Biringer K, Skerenova M, et al. (2015). Different models of inheritance in selected genes in patients with sticky platelet syndrome and fetal loss. Semin Thromb Hemost 41:330–5
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. (2010). Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456–62
   PubMed Web of Science ®Google Scholar
• Storey RF, Melissa Thornton S, Lawrance R, et al. (2009). Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 20:341–8
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Wei C, et al. (2010). First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 3:556–66
   PubMed Web of Science ®Google Scholar
• Tregouet DA, Garelle V. (2007). A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 23:1038–9
   PubMed Web of Science ®Google Scholar
• Varenhorst C, Eriksson N, Johansson A, et al. (2015). Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J 36:1901–12
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–57
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF; Plato Investigators, et al. (2010). Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376:1320–8
   PubMed Web of Science ®Google Scholar
• Wurtz M, Nissen PH, Grove EL, et al. (2014). Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS One 9:e111816
   PubMed Web of Science ®Google Scholar
• Xiang Q, Cui Y, Zhao X, Zhao N. (2013). Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics 14:1179–89
   PubMed Web of Science ®Google Scholar
• Yao Y, Tang XF, Zhang JH, et al. (2016). Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thromb Res 141:28–34
   PubMed Web of Science ®Google Scholar
• Zang M, Zhao L, Zhu F, et al. (2015). Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects. Drug Metab Pharmacokinet 30:123–6
   PubMed Web of Science ®Google Scholar